GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
HengRui presses on in HER3, despite Merck’s failure
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
World Lung 2025 – Ideaya challenges Zai Lab
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
Genor goes one better
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
